Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clon.2023.03.017 | DOI Listing |
Curr Oncol Rep
January 2025
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan.
Purpose Of Review: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC.
Recent Findings: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response.
Cureus
November 2024
Department of Medicine, Division of Gastroenterology and Hepatology, Penn State College of Medicine, Hershey, USA.
Background Our aim was to assess the clinical presentation and outcomes of patients with a manometric diagnosis of esophagogastric junction outflow obstruction (EGJOO) using standardized symptom surveys and comparison to a cohort who were referred for manometry but who had a normal study. Methods We followed a cohort of adult patients without a mechanical obstruction who underwent high-resolution manometry at our medical center from 9/12/19 to 10/4/21 for 16 months. Results Thirty-seven patients with EGJOO (age: 60.
View Article and Find Full Text PDFGastric Cancer
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Background: Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate the prevalence and clinicopathological features of chemotherapy-naïve metastatic or recurrent MSI-high GC as a prescreening study for a phase II trial of nivolumab plus ipilimumab.
Methods: Key inclusion criteria included metastatic or recurrent adenocarcinoma of GC, ECOG performance status of 0 or 1, and no prior systemic therapy for metastatic or recurrent disease.
Front Oncol
December 2024
Department of Gastroenterology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a rare and highly aggressive malignancy characterized by both exocrine and neuroendocrine components. Treatment options for metastatic cases are limited, with typical therapeutic approaches involving a combination of chemotherapy and immunotherapy. A 68-year-old male with metastatic gastric MANEC was treated with targeted therapy, immunotherapy, and chemotherapy, including S-1, apatinib, cadonilimab, and paclitaxel.
View Article and Find Full Text PDFUpdates Surg
December 2024
Surgery Clinic 3, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", "Iuliu Hațieganul" University of Medicine and Pharmacy, 400394, Cluj-Napoca-Napoca, Romania.
Patients with esophageal cancer and concomitant liver cirrhosis (LC) pose a surgical challenge because of the increased risk of postoperative complications and mortality. Purpose of this study was to review the existing literature and estimate perioperative short-term outcomes of esophagectomy in this patient population. Systematic review and meta-analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!